inquiry@genetargeting.com
+1 (631) 468-8530

Double Immune Checkpoint Humanized Mice


Targeted humanized mice, now available in less time.

As part of ingenious targeting laboratory’s collaboration with Shanghai Model Organisms Center, Inc., we offer double immune checkpoint humanized mice. These research-ready, genetically modified models are an affordable, convenient option for your next experiment.

Available on the widely used C57BL/6 background, our double immune checkpoint models are ideal for many different kinds of human disease and drug efficacy studies. No matter which catalog mouse model you choose, you can expect reliable and translational results.

Reasons to purchase catalog humanized mice at ingenious

Both ingenious and SMOC have been established as providers of genetically modified mouse models for over 20 years.
Our double immune checkpoint humanized mice are among some of the most affordable catalog models in North America and Europe.
Compared to other vendors, all of our immune checkpoint models are on the pure C57/BL6 background. We also offer BALB/c as well for some of the lines.
You can expect much faster timelines when purchasing off-the-shelf models compared to generating a new custom model.
We have a large selection of strains for research studies in cancer, immunotherapy, drug screening, and more.
Our team of scientific consultants has the expertise you seek when evaluating options for your next mouse model. Inquire today!

Double immune checkpoint humanized models at ingenious:

If you are interested in drug efficacy studies for these models, please contact us at inquiry@genetargeting.com.

Strain NameCatalog No.DataPrice
OX40/CTLA4IT-HU-00105PDF
PD-1/4-1BBIT-HU-200279PDF
PD-1/CD40IT-HU-190017PDF
PD-1/CTLA4IT-HU-00079PDF
PD-1/LAG3IT-HU-00101PDF
PD-1/OX40IT-HU-00108PDF
PD-1/PD-L1IT-HU-00100PDF
PD-1/TIGITIT-HU-00104PDF
PD-1/TIM3IT-HU-00103PDF
PD-L1/CTLA4IT-HU-00102PDF
PD-L1/LAG3IT-HU-00137PDF
PD-L1/OX40IT-HU-00111PDF
PD-L1/TIGITIT-HU-18013PDF
SIRPA/CD47IT-HU-190019PDF

Share With Your Circle!

Shares
Shares